Literature DB >> 1673980

Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits.

R L Geller1, M J Smyth, S L Strobl, F H Bach, F W Ruscetti, D L Longo, A C Ochoa.   

Abstract

CD4+ and CD8+ T cells do not develop significant lymphokine-activated killer (LAK) activity when PBL are cultured with IL-2 or even when they are activated with a T cell stimulus such as OKT3 mAb. The possibility that a T cell regulatory mechanism prevents the development of LAK activity by CD4+ or CD8+ cells in OKT3 mAb and IL-2 cultures was tested by depleting CD8+ or CD4+ cells from PBL before stimulation with OKT3 and IL-2. Under these conditions, the remaining CD4+ and CD8+ cells were able to generate non-MHC-restricted lysis of NK-resistant tumor targets. Our data suggested that a regulatory signal was present in the culture to prevent the development of lytic function by T cells. T cells removed from the PBL cultures were, upon culture with IL-2, able to generate high LAK activity, suggesting that inhibition of the CD4+ or CD8+ T cell-mediated LAK activity was an active ongoing process, which blocked the lysis at the level of the activated cell and not the precursor cell. Mixing experiments demonstrated that the CD4+ or the CD8+ cells isolated from the PBL cultures were able to inhibit the development of lytic function in the CD4-depleted and CD8-depleted cultures. Transforming growth factor-beta (TGF-beta) has been shown to block LAK activity of NK cells in IL-2-stimulated cultures. When TGF-beta was added to CD4(+)- or CD8(+)-depleted cultures, it also inhibited LAK activity of T cells in a dose-dependent fashion, without interfering with T cell growth. Lytic activity returned to activated levels when TGF-beta was removed from the culture medium, thereby demonstrating the reversibility of TGF-beta inhibition.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673980

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo.

Authors:  J A Mikovits; N C Lohrey; R Schulof; J Courtless; F W Ruscetti
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

2.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.

Authors:  Slawomir Wojtowicz-Praga
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

4.  Neutralization of transforming growth factor beta 1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro.

Authors:  T Kanto; T Takehara; K Katayama; A Ito; K Mochizuki; N Kuzushita; T Tatsumi; Y Sasaki; A Kasahara; N Hayashi; M Hori
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

5.  Augmentation by transferrin of IL-2-inducible killer activity and perforin production of human CD8+ T cells.

Authors:  A Nakamura; S Sone; R Nabioullin; K Sugihara; M Munekata; Y Nishioka; A Nii; T Ogura
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

6.  Improvement of macrophage dysfunction by administration of anti-transforming growth factor-beta antibody in EL4-bearing hosts.

Authors:  H Maeda; S Tsuru; A Shiraishi
Journal:  Jpn J Cancer Res       Date:  1994-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.